VC View: Deal-Making During A Pandemic And 2021 Expectations
Interview With Naseem Amin And Christian Schetter
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
You may also be interested in...
Iterum Anxiously Awaiting Other Results After SURE 3 Failure
Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.
VelosBio CEO: Series A Success Shows Investors Back His ADC Formula
VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.
Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic
Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.